Switch theme
Sign up to access all valuation multiples
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
1992
1.8K+
LTM Revenue $2.5B
LTM EBITDA $629M
$11.7B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Neurocrine Biosciences has a last 12-month revenue (LTM) of $2.5B and a last 12-month EBITDA of $629M.
In the most recent fiscal year, Neurocrine Biosciences achieved revenue of $2.4B and an EBITDA of $640M.
Neurocrine Biosciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Neurocrine Biosciences valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $2.5B | XXX | $2.4B | XXX | XXX | XXX |
| Gross Profit | $2.5B | XXX | $2.3B | XXX | XXX | XXX |
| Gross Margin | 98% | XXX | 99% | XXX | XXX | XXX |
| EBITDA | $629M | XXX | $640M | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | 27% | XXX | XXX | XXX |
| EBIT | $544M | XXX | $583M | XXX | XXX | XXX |
| EBIT Margin | 22% | XXX | 25% | XXX | XXX | XXX |
| Net Profit | $365M | XXX | $341M | XXX | XXX | XXX |
| Net Margin | 15% | XXX | 14% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Neurocrine Biosciences's stock price is $123.
Neurocrine Biosciences has current market cap of $12.2B, and EV of $11.7B.
See Neurocrine Biosciences trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $11.7B | $12.2B | XXX | XXX | XXX | XXX | $3.58 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Neurocrine Biosciences has market cap of $12.2B and EV of $11.7B.
Neurocrine Biosciences's trades at 5.0x EV/Revenue multiple, and 18.2x EV/EBITDA.
Equity research analysts estimate Neurocrine Biosciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Neurocrine Biosciences has a P/E ratio of 33.3x.
See valuation multiples for Neurocrine Biosciences and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $12.2B | XXX | $12.2B | XXX | XXX | XXX |
| EV (current) | $11.7B | XXX | $11.7B | XXX | XXX | XXX |
| EV/Revenue | 4.7x | XXX | 5.0x | XXX | XXX | XXX |
| EV/EBITDA | 18.6x | XXX | 18.2x | XXX | XXX | XXX |
| EV/EBIT | 21.4x | XXX | 20.0x | XXX | XXX | XXX |
| EV/Gross Profit | 4.8x | XXX | n/a | XXX | XXX | XXX |
| P/E | 33.3x | XXX | 35.7x | XXX | XXX | XXX |
| EV/FCF | 22.9x | XXX | 20.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialNeurocrine Biosciences's last 12 month revenue growth is 14%
Neurocrine Biosciences's revenue per employee in the last FY averaged $1.3M, while opex per employee averaged $1.0M for the same period.
Neurocrine Biosciences's rule of 40 is 33% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Neurocrine Biosciences's rule of X is 61% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Neurocrine Biosciences and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 14% | XXX | 15% | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | 27% | XXX | XXX | XXX |
| EBITDA Growth | 0% | XXX | 19% | XXX | XXX | XXX |
| Rule of 40 | 33% | XXX | 42% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 61% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 31% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 74% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Neurocrine Biosciences acquired XXX companies to date.
Last acquisition by Neurocrine Biosciences was XXXXXXXX, XXXXX XXXXX XXXXXX . Neurocrine Biosciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Neurocrine Biosciences founded? | Neurocrine Biosciences was founded in 1992. |
| Where is Neurocrine Biosciences headquartered? | Neurocrine Biosciences is headquartered in United States of America. |
| How many employees does Neurocrine Biosciences have? | As of today, Neurocrine Biosciences has 1.8K+ employees. |
| Who is the CEO of Neurocrine Biosciences? | Neurocrine Biosciences's CEO is Dr. Kyle W. Gano, PhD. |
| Is Neurocrine Biosciences publicy listed? | Yes, Neurocrine Biosciences is a public company listed on NAS. |
| What is the stock symbol of Neurocrine Biosciences? | Neurocrine Biosciences trades under NBIX ticker. |
| When did Neurocrine Biosciences go public? | Neurocrine Biosciences went public in 1996. |
| Who are competitors of Neurocrine Biosciences? | Similar companies to Neurocrine Biosciences include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Neurocrine Biosciences? | Neurocrine Biosciences's current market cap is $12.2B |
| What is the current revenue of Neurocrine Biosciences? | Neurocrine Biosciences's last 12 months revenue is $2.5B. |
| What is the current revenue growth of Neurocrine Biosciences? | Neurocrine Biosciences revenue growth (NTM/LTM) is 14%. |
| What is the current EV/Revenue multiple of Neurocrine Biosciences? | Current revenue multiple of Neurocrine Biosciences is 4.7x. |
| Is Neurocrine Biosciences profitable? | Yes, Neurocrine Biosciences is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Neurocrine Biosciences? | Neurocrine Biosciences's last 12 months EBITDA is $629M. |
| What is Neurocrine Biosciences's EBITDA margin? | Neurocrine Biosciences's last 12 months EBITDA margin is 25%. |
| What is the current EV/EBITDA multiple of Neurocrine Biosciences? | Current EBITDA multiple of Neurocrine Biosciences is 18.6x. |
| What is the current FCF of Neurocrine Biosciences? | Neurocrine Biosciences's last 12 months FCF is $509M. |
| What is Neurocrine Biosciences's FCF margin? | Neurocrine Biosciences's last 12 months FCF margin is 20%. |
| What is the current EV/FCF multiple of Neurocrine Biosciences? | Current FCF multiple of Neurocrine Biosciences is 22.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
